Medannex
- Company typePrivate
- Founded2009
- HeadquartersEdinburgh, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Medannex firmographics
Firmographics- Name
- Medannex
- Website
- https://medannex.org
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Medannex industry classification
Industry- Product category
- Pediatric Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Medannex is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Medannex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Medannex product offering
Product offeringCore offering
Medannex is developing MDX-124, a first-in-class drug candidate targeting annexin-A1 for the treatment of pediatric osteosarcoma, a rare childhood bone cancer. The therapy is being advanced toward clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.
Product overview
Medannex is a biopharmaceutical company developing MDX-124, a first-in-class drug candidate targeting pediatric osteosarcoma. The company is advancing this therapy toward clinical trials with support from an Innovate UK grant, building on prior evaluation in adult cancer studies.
Differentiator
Problem solved
Functional benefit
Products and services
- MDX-124 First-in-class drug candidate targeting annexin-A1, being developed as a novel treatment for pediatric osteosarcoma, a rare childhood bone cancer. The candidate is being prepared for clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.
Quantifiable outcome
- Targeted improvement in survival rates among children with osteosarcoma
Companies that use Medannex
Customer profileSegments1 record
Ideal customer profiles1 record
Medannex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Medannex partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Medannex competitors and assessment
Company assessmentDirect peers
- Y-mAbs Therapeutics: Y-mAbs is a commercial-stage biopharmaceutical company developing antibody-based therapeutics for pediatric cancers. It is highly comparable to Medannex in target patient population (children with cancer) and oncology focus, though at a more advanced stage with marketed products.
- Day One Biopharmaceuticals: Day One Biopharmaceuticals is a clinical-stage company specifically focused on developing targeted therapies for pediatric cancers and rare diseases of childhood. Its mission, patient focus, and stage are directly aligned with Medannex's pediatric osteosarcoma program.
- Salarius Pharmaceuticals: Salarius develops treatments for rare pediatric cancers including Ewing sarcoma, another childhood bone/soft-tissue cancer with similar biology and patient population to osteosarcoma. Both companies target underserved pediatric sarcomas.
- Kazia Therapeutics: Kazia Therapeutics develops oncology therapies with a particular focus on pediatric brain cancers (diffuse midline gliomas). It is a directly comparable small-cap, single-indication pediatric oncology biotech with similar funding scale.
- Oncternal Therapeutics: Oncternal develops oncology therapies for rare and difficult-to-treat cancers, including Ewing sarcoma. Its rare-pediatric-cancer focus and small-cap, single-asset profile closely mirror Medannex's positioning.
- Marker Therapeutics: Marker Therapeutics is a clinical-stage immuno-oncology company with programs in both adult and pediatric cancers, including sarcoma indications. Comparable as a small oncology biotech targeting cancer through novel mechanisms.
- Cyclacel Pharmaceuticals: Cyclacel develops small-molecule medicines for cancer, with historical emphasis on pediatric and rare leukemias. Comparable as a small-cap, clinical-stage oncology biotech focused on underserved indications.
Broad incumbents
- MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. While larger and with a broader pipeline, it operates in the same oncology drug development space with novel mechanisms.
- Deciphera Pharmaceuticals: Deciphera is a commercial-stage oncology company developing kinase inhibitors for cancer treatment. Comparable as an established oncology drug developer with a focus on targeted therapies, though at a more advanced stage and broader portfolio.
- BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with a portfolio of approved therapies for serious and life-threatening conditions, including pediatric indications. Relevant as an established leader in rare pediatric disease drug development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
Medannex social profiles
Digital presenceMedannex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medannex leadership team
Management profileNumber of profiles
Profiles2 records
Medannex funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medannex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medannex
What does Medannex do?
Medannex is developing MDX-124, a first-in-class drug candidate targeting annexin-A1 for the treatment of pediatric osteosarcoma, a rare childhood bone cancer. The therapy is being advanced toward clinical trials based on promising preclinical results and prior evaluation in adult cancer studies.
Is Medannex a public or private company?
Medannex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medannex founded?
Medannex was founded in 2009. It employs 11 to 50 people.
Where is Medannex based?
Medannex is headquartered in Edinburgh, United Kingdom, in the Europe region.
Who are Medannex's main competitors?
Direct peers on record are Y-mAbs Therapeutics, Day One Biopharmaceuticals, Salarius Pharmaceuticals, Kazia Therapeutics, Oncternal Therapeutics, Marker Therapeutics and Cyclacel Pharmaceuticals. Broad incumbents are MacroGenics, Deciphera Pharmaceuticals and BioMarin Pharmaceutical.
Does Medannex have an API?
No public API is recorded for Medannex.
What industry is Medannex in?
Medannex's product category is Pediatric Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714.